Paper7965656
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
Wasan KM and 3 others. J Pharm Sci, 1994. Cited by 72 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. Papers, record 7965656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7965656
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amphotericin B | Major topic |
| Carrier Proteins | Major topic |
| Lipoproteins, HDL | Major topic |
| Animals | |
| Apolipoprotein A-I | |
| Cells, Cultured | |
| Cholesterol Esters | |
| Deoxycholic Acid | |
| Drug Carriers | |
| Humans | |
| Iodine Radioisotopes | |
| Kidney | |
| Kinetics | |
| Lipoproteins, LDL | |
| Liposomes | |
| Receptors, LDL | |
| Surface Properties | |
| Swine |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| HL29582 | NHLBI NIH HHS | United States | P01HL029582 | PubMed and NIH |
Source NIH RePORTER
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,243,314 | Protein-mediated stabilization of amphotericin B increases its efficacy against diverse fungal pathogens. | Microbiol Spectr | 2025 | https://conductscience.org/library/papers/40243314 | PubMed |
| 36,411,251 | Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/36411251 | PubMed |
| 36,211,958 | Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36211958 | PubMed |
| 31,906,268 | Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/31906268 | PubMed |
| 31,118,866 | Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis. | Res Rep Trop Med | 2019 | https://conductscience.org/library/papers/31118866 | PubMed |
| 29,317,800 | Leishmaniasis in humans: drug or vaccine therapy? | Drug Des Devel Ther | 2018 | https://conductscience.org/library/papers/29317800 | PubMed |
| 29,261,103 | Calli Essential Oils Synergize with Lawsone against Multidrug Resistant Pathogens. | Molecules | 2017 | https://conductscience.org/library/papers/29261103 | PubMed |
| 27,855,062 | Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/27855062 | PubMed |
| 27,697,762 | Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27697762 | PubMed |
| 26,818,726 | Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. | Drugs | 2016 | https://conductscience.org/library/papers/26818726 | PubMed |
| 25,788,110 | Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). | Drug Deliv Transl Res | 2011 | https://conductscience.org/library/papers/25788110 | PubMed |
| 25,093,386 | Sub-emetic toxicity of Bacillus cereus toxin cereulide on cultured human enterocyte-like Caco-2 cells. | Toxins (Basel) | 2014 | https://conductscience.org/library/papers/25093386 | PubMed |
| 23,703,346 | Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. | Indian J Med Res | 2013 | https://conductscience.org/library/papers/23703346 | PubMed |
| 17,722,276 | Optimizing efficacy of amphotericin B through nanomodification. | Int J Nanomedicine | 2006 | https://conductscience.org/library/papers/17722276 | PubMed |
| 15,648,266 | Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex. | Pharm Res | 2004 | https://conductscience.org/library/papers/15648266 | PubMed |
| 11,850,269 | Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/11850269 | PubMed |
| 11,850,268 | Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/11850268 | PubMed |
| 11,741,206 | Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form. | AAPS PharmSci | 1999 | https://conductscience.org/library/papers/11741206 | PubMed |
| 11,709,329 | Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11709329 | PubMed |
| 11,683,244 | The effect of serum albumin on amphotericin B aggregate structure and activity. | Pharm Res | 2001 | https://conductscience.org/library/papers/11683244 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| APOA1 | 335 | PubTator's text mining | https://conductscience.org/library/genes/335 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7965656
GET https://conductscience.org/api/papers/v1/7965656/cited_by?page=2